Exploring beliefs and attitudes about genetic testing in leiomyosarcoma patients
Beliefs, Attitudes, and Response to Genetic Testing in Sarcoma Patients
This study looks at what leiomyosarcoma patients and their families think about genetic testing and how it might affect their understanding of cancer risk.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Utah Academic / other |
| Locations | 1 site (Salt Lake City, Utah) |
| Trial ID | NCT06875700 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the beliefs and attitudes of leiomyosarcoma (LMS) patients regarding the heritability of their condition and their interest in genetic testing. It aims to assess the cognitive and emotional impacts of receiving genetic information, particularly focusing on patients who have actionable germline pathogenic variants. Additionally, the study evaluates the perspectives of family members concerning genetic testing and its implications for cancer risk. By understanding these attitudes, the research seeks to inform better integration of genetic testing into patient care.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 or older with leiomyosarcoma who have actionable germline pathogenic variants and have not undergone prior testing for these variants.
Not a fit: Patients under 18 years old or those who have previously undergone germline testing for the same pathogenic variant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of genetic predispositions in leiomyosarcoma patients, leading to improved screening and preventive measures for at-risk relatives.
How similar studies have performed: Previous studies have indicated a strong interest in genetic testing among cancer patients, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion LMS Proband * Actionable germline PV detected in the research context * Living * No prior germline testing for this PV * Able to speak and read English * Mentally competent * Age 18 or older Relative of LMS Proband * 25-50% chance for having inherited the PV * No prior germline testing for this PV * Able to speak and read English * Mentally competent * Age 18 or older Exclusion (both cohorts) * \<18 years * Unable to read or write
Where this trial is running
Salt Lake City, Utah
- Huntsman Cancer Institute at the University of Utah — Salt Lake City, Utah, United States (Recruiting)
Study contacts
- Study coordinator: Gregg Wood
- Email: gregg.wood@hci.utah.edu
- Phone: 8016464215
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.